WASHINGTON — Robert F. Kennedy Jr. spent the early months of 2026 canceling every mRNA project he could reach from his position at the Department of Health and Human Services. The Food and Drug Administration followed with a formal letter refusing to review Moderna’s flu vaccine application, a procedural block that, if sustained, would have kept mRNA technology out of flu shots for at least another season.
Then, on August 5, the FDA approved it anyway.
mFlusiva, Moderna’s mRNA-1010, became the first messenger RNA influenza vaccine cleared for use in the United States. As the FDA noted in its announcement, the agency authorized it for adults 50 and older, covering the 2026–27 flu season. Standard approval applies to adults between 50 and 64. For adults 65 and older, authorization came through the accelerated approval pathway, which allows clearance based on reasonably likely evidence of benefit while requiring Moderna to deliver postmarketing confirmation across two flu seasons.
The approval came after the FDA’s independent advisory committee voted unanimously in June to recommend the vaccine, a clean scientific verdict that cleared the way for the August decision. NBC News, in its report on the approval, noted that career staff at the agency worked through the advisory process independently of political leadership.
The trial data is straightforward. In a phase three study of more than 26,000 adults age 50 and older, mFlusiva demonstrated 27 percent greater relative vaccine effectiveness against laboratory-confirmed influenza illness compared with a standard-dose quadrivalent shot. In adults 65 and older, the population carrying the greatest risk from severe flu, effectiveness came in at 27.4 percent higher than the comparator. NPR, in its coverage of the approval, described the advisory committee process that preceded the FDA’s decision.
Those margins are meaningful without being dramatic. Standard-dose flu vaccines already prevent tens of thousands of hospitalizations and deaths each year. A 27 percent improvement, applied across the tens of millions of Americans who receive flu shots annually, translates into a significant number of prevented illnesses, though exactly how many depends on which strains circulate in a given season, which no study can predict in advance.
The accelerated approval for adults 65 and older is worth understanding clearly. It is not a cautionary label or a use restriction. Older adults may receive mFlusiva. What the designation means is that Moderna must complete an additional two-season postmarketing study to confirm that the effectiveness seen in trials holds across different flu strain years. Physicians advising patients in that age group should also discuss existing high-dose and adjuvanted options alongside mFlusiva, as Fluzone High-Dose and Fluad both carry standard approval for adults 65 and older. No head-to-head comparison between mFlusiva and those formulations has yet been published.
The mRNA platform offers one advantage no existing flu vaccine has: speed of antigen design. Traditional formulations require growing the influenza virus in eggs or cell culture, a process that takes months and introduces the possibility that the virus mutates during production, reducing the match between vaccine and circulating strain. mRNA vaccines encode the genetic instructions for the antigen directly, allowing production to begin within days of a confirmed strain selection. In a year when the annual strain decision misses its target, that design-to-manufacture speed could matter more than any trial comparison suggests.
Research on other vaccines is expanding the picture of what immunization can do for older adults beyond direct infection prevention. The shingles vaccine, in a 500,000-person study, was found to reduce dementia risk by 24 percent in adults over 65, a benefit researchers linked to the varicella-zoster virus’s role in triggering neurological inflammation. Whether mFlusiva or other influenza vaccines carry similar downstream cognitive benefits is not yet known. That question is now a live area of investigation.
Moderna has confirmed that mFlusiva will be available at U.S. pharmacies and healthcare settings for the 2026–27 season. Pricing and Medicare Part B reimbursement structure have not been finalized. Regulatory reviews are underway in Europe, Canada, and Australia.
Flu vaccination rates in the United States hover around 50 percent for adults broadly, and uptake of the enhanced formulations already available for older adults has been uneven despite existing Medicare coverage. Adding a new and better option does not automatically change those behavioral patterns. The gap between what a vaccine offers and what the population actually receives remains the most persistent failure point in flu prevention.
What mFlusiva’s approval marks, undeniably, is the mRNA platform’s first successful expansion beyond the pandemic that proved it. COVID-19 was the proving ground. An annual respiratory pathogen, with a new strain selection challenge every season, a different competitive landscape, and a different political climate around it, is its first real test of durability.
The FDA’s approval survived attempts that, in an earlier regulatory era, would likely not have materialized. What that survival says about the boundary between scientific review and political direction at the agency is a question the August decision alone cannot answer.
Related Posts
